Editas Medicine Inc Sustainability Reports
Editas Medicine, Inc. operates as a clinical-stage genome editing company focused on developing transformative genomic medicines. The company leverages CRISPR technology to discover and develop therapies that correct disease-causing genes.
Sector: Professional & technical services
Country: United States
Exchange: Nasdaq
LEI: 5299000AON4Q9NT2JE42
FIGI: BBG005MX5H08
4 reports from 2018 to 2023
